Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Cediranib (Primary) ; Selumetinib (Primary)
- Indications Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Neuroendocrine carcinoma; Osteosarcoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
- Focus Adverse reactions
Most Recent Events
- 21 Mar 2025 Planned End Date changed from 7 Mar 2025 to 19 Mar 2026.
- 21 Mar 2025 Planned End Date changed from 7 Mar 2025 to 19 Mar 2026.
- 08 Mar 2024 Planned End Date changed from 1 Jun 2016 to 7 Mar 2025.